Fluorodeoxyglucose positron emission tomography in Richardson’s syndrome and progressive supranuclear palsy-parkinsonism

Mov Disord. 2012 Jan;27(1):151-5. doi: 10.1002/mds.23975.

Abstract

Background: We hypothesized that postural instability and cognitive decline in patients with Richardson’s syndrome could be a consequence of reduced thalamic and frontal metabolism. Severe Parkinsonian signs in patients with progressive supranuclear palsy-parkinsonism may be reflected by alterations in putaminal metabolism.

Methods: Eleven patients with Richardson’s syndrome, 8 patients with progressive supranuclear palsy-parkinsonism, 12 with Parkinson’s disease, and 10 controls underwent clinical assessment and fluorodeoxyglucose positron emission tomography (PET).

Results: Richardson’s syndrome patients showed pronounced thalamic hypometabolism, and patients with progressive supranuclear palsy-parkinsonism pronounced putaminal hypometabolism, compared to all other investigated groups. The putamen/thalamus uptake ratio differentiated progressive supranuclear palsy-parkinsonism from Richardson’s syndrome (area under the curve 5 0.86) and from Parkinson’s disease (area under the curve 5 0.80) with acceptable accuracy. Frontal hypometabolism was predominantly found in Richardson’s syndrome patients.

Conclusions: Richardson’s syndrome, progressive supranuclear palsy-parkinsonism and Parkinson’s disease showed different metabolic patterns in fluorodeoxyglucose PET.

MeSH terms

  • Aged
  • Brain / diagnostic imaging*
  • Brain / pathology
  • Female
  • Fluorodeoxyglucose F18*
  • Humans
  • Male
  • Middle Aged
  • Parkinson Disease* / complications
  • Parkinson Disease* / diagnostic imaging
  • Parkinson Disease* / pathology
  • Positron-Emission Tomography*
  • Putamen / diagnostic imaging
  • ROC Curve
  • Severity of Illness Index
  • Supranuclear Palsy, Progressive* / complications
  • Supranuclear Palsy, Progressive* / diagnostic imaging
  • Supranuclear Palsy, Progressive* / pathology
  • Thalamus / diagnostic imaging

Substances

  • Fluorodeoxyglucose F18